Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The transcription factor NF-κB activates a number of genes whose protein products are proinflammatory. In quiescent cells, NF-κB exists in a latent form and is activated via a signal-dependent proteolytic mechanism in which the inhibitory protein IκB is degraded by the ubiquitin–proteasome pathway. Consequently, inhibition of the proteasome suppresses activation of NF-κB. This suppression should therefore decrease transcription of many genes encoding proinflammatory proteins and should ultimately have an anti-inflammatory effect. To this end, a series of peptide boronic acid inhibitors of the proteasome, exemplified herein by PS-341, were developed. The proteasome is the large multimeric protease that catalyzes the final proteolytic step of the ubiquitin–proteasome pathway. PS-341, a potent, competitive inhibitor of the proteasome, readily entered cells and inhibited the activation of NF-κB and the subsequent transcription of genes that are regulated by NF-κB. Significantly, PS-341 displayed similar effects in vivo. Oral administration of PS-341 had anti-inflammatory effects in a model of Streptococcal cell wall-induced polyarthritis and liver inflammation in rats. The attenuation of inflammation in this model was associated with an inhibition of IκBα degradation and NF-κB-dependent gene expression. These experiments clearly demonstrate that the ubiquitin–proteasome pathway and NF-κB play important roles in regulating chronic inflammation and that, as predicted, proteasome inhibition has an anti-inflammatory effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
Barnes, P. J., & Karin, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361506 · Cited by 4,669
Baeuerle, P. A., & Baltimore, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81318-5 · Cited by 3,001
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Self-citationThe HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
Scheffner, M., Huibregtse, J. M., Vierstra, R. D., & Howley, P. M. (1993) · Cell · doi:10.1016/0092-8674(93)90384-3 · Cited by 2,054
Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids
Scheinman, R. I., Cogswell, P. C., Lofquist, A. K., & Baldwin, A. S. (1995) · Science · doi:10.1126/science.270.5234.283 · Cited by 1,699
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583
The Proteasome: Paradigm of a Self-Compartmentalizing Protease
Baumeister, W., Walz, J., Zühl, F., & Seemüller, E. (1998) · Cell · doi:10.1016/s0092-8674(00)80929-0 · Cited by 1,494
Cited by
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng, L., Mohan, R., Kwok, B. H. B., Elofsson, M., Sin, N., & Crews, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10403 · Cited by 920
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Self-citationChauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway
Maggio, M., Guralnik, J. M., Longo, D. L., & Ferrucci, L. (2006) · The Journals of Gerontology: Series A · doi:10.1093/gerona/61.6.575 · Cited by 692
Synovial fibroblasts: key players in rheumatoid arthritis
Huber, L. C., Distler, O., Tarner, I., Gay, R. E., Gay, S., & Pap, T. (2006) · Rheumatology · doi:10.1093/rheumatology/kel065 · Cited by 607
Muchamuel, T., Basler, M., Aujay, M. A., Suzuki, E., Kalim, K. W., Lauer, C., Sylvain, C., Ring, E. R., Shields, J., Jiang, J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1978 · Cited by 599
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.003 · Cited by 527
Boronic acid compounds as potential pharmaceutical agents
Yang, W., Gao, X., & Wang, B. (2003) · Medicinal Research Reviews · doi:10.1002/med.10043 · Cited by 502
Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology
Schwartz, A. L., & Ciechanover, A. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.051208.165340 · Cited by 492
Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104950 · Cited by 454
I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation
Grisham, M. B., Jourd’Heuil, D., & Wink, D. A. (1999) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1999.276.2.g315 · Cited by 450
Self-citationThe ubiquitin‐proteasome pathway and proteasome inhibitors
Myung, J., Kim, K. B., & Crews, C. M. (2001) · Medicinal Research Reviews · doi:10.1002/med.1009 · Cited by 446
The Transcription Factor NF-κB and the Regulation of Vascular Cell Function
de Martin, R., Hoeth, M., Hofer-Warbinek, R., & Schmid, J. A. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.11.e83 · Cited by 408
20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development
Borissenko, L., & Groll, M. (2007) · Chemical Reviews · doi:10.1021/cr0502504 · Cited by 407
Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204623 · Cited by 394
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Everly, M. J., Everly, J. J., Susskind, B., Brailey, P., Arend, L. J., Alloway, R. R., Roy-Chaudhury, P., Govil, A., Mogilishetty, G., Rike, A. H., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318190af83 · Cited by 392
Jung, T., Catalgol, B., & Grune, T. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.001 · Cited by 389
Withaferin A is a potent inhibitor of angiogenesis
Mohan, R., Hammers, H., Bargagna-mohan, P., Zhan, X., Herbstritt, C., Ruiz, A., Zhang, L., Hanson, A., Conner, B., Rougas, J., et al. (2004) · Angiogenesis · doi:10.1007/s10456-004-1026-3 · Cited by 382
Aging and Immune Function: Molecular Mechanisms to Interventions
Ponnappan, S., & Ponnappan, U. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3228 · Cited by 339
“Interest in the UPP for immunologists has been stimulated by the recognition that besides maintenance of proteostasis, the generation of antigenic peptides, the regulation of key proteins that regulate cell cycle (p27 kip, p21), apoptosis, cell transformation (p53), and gene transcription (NFκB), is also involved in t…”
BackgroundDiscovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle
Owa, T., Yoshino, H., Okauchi, T., Yoshimatsu, K., Ozawa, Y., Sugi, N. H., Nagasu, T., Koyanagi, N., & Kitoh, K. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9902638 · Cited by 322
NF-κB Signaling Regulates Physiological and Pathological Chondrogenesis
Jimi, E., Huang, F., & Nakatomi, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246275 · Cited by 321
Bharti, A. C., Shishodia, S., Reuben, J. M., Weber, D., Alexanian, R., Raj-Vadhan, S., Estrov, Z., Talpaz, M., & Aggarwal, B. B. (2004) · Blood · doi:10.1182/blood-2003-06-2151 · Cited by 318
Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
Proteasome Inhibition Measurements: Clinical Application
Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., & Elliott, P. J. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.5.673 · Cited by 301
Self-citationTHE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY
Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141300 · Cited by 247
Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis
Campbell, I. K., Gerondakis, S., O’Donnell, K., & Wicks, I. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8298 · Cited by 168
“Our results support several previous studies that indicate total Rel/NF-κB blockade would prevent inflammatory arthritis (31, 42, 49).”
McCartney-Francis, N., Jin, W., & Wahl, S. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3814 · Cited by 101
Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases
Vij, N., Min, T., Bodas, M., Gorde, A., & Roy, I. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.06.008 · Cited by 85
Naujokat, C., Berges, C., Höh, A., Wieczorek, H., Fuchs, D., Ovens, J., Miltz, M., Sadeghi, M., Opelz, G., & Daniel, V. (2007) · Immunology · doi:10.1111/j.1365-2567.2006.02487.x · Cited by 41
Molecular Pathogenesis of Multiple Myeloma
Maura, F., & Bergsagel, P. L. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.010 · Cited by 19
Metadata
- Authors
- Palombella, V. J., Conner, E. M., Fuseler, J. W., Destree, A., Davis, J. M., Laroux, F. S., Wolf, R. E., Huang, J., Brand, S., Elliott, P. J., Lazarus, D., McCormack, T., Parent, L., Stein, R., Adams, J., & Grisham, M. B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-12-22
- Volume
- 95
- Issue
- 26
- Pages
- 15671-15676
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2103185055
- Cited by
- 287
- References
- 45
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.